108_CD
Alliance_NN
UniChem_NN
Plc_NN
Notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
47_CD
RELATED_VBN
PARTY_NN
DISCLOSURES_NN
CONTINUED_VBD
Key_NN
management_NOMZ
remuneration_NOMZ
The_DT
remuneration_NOMZ
of_PIN
the_DT
executive_NN
Directors_NN
,_,
who_WP
are_VPRT [BEMA]
the_DT
key_JJ
management_NOMZ
personnel_NN
of_PIN
the_DT
Group_NN
,_,
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
in_PIN
aggregate_NN
for_PIN
each_QUAN
of_PIN
the_DT
categories_NN
specified_VBN [WZPAST]
by_PIN
IAS_NN
24_CD
Related_NN
Party_NN
Disclosures_NN
._.
Further_JJ
information_NOMZ
regarding_VBG [WZPRES]
the_DT
individual_JJ
remuneration_NOMZ
of_PIN
individual_JJ
Directors_NN
is_VPRT [PASS]
provided_VBN
in_PIN
the_DT
Board_NN
report_NN
on_PIN
remuneration_NOMZ
._.
2005_CD
2004_CD
million_CD
million_CD
Short-term_JJ
employee_NN
benefits_NN
3.8_CD
3.7_CD
Post-employment_NOMZ
benefits_NN
1.1_CD
0.6_CD
Other_JJ
long-term_JJ
benefits_NN
Termination_NOMZ
benefits_NN
0.5_CD
0.8_CD
Share-based_JJ
compensation_NOMZ
charge_NN
2.1_CD
0.8_CD
7.5_CD
5.9_CD
48_CD
CONTINGENT_NN
LIABILITIES_NOMZ
The_NN
Group_NN
offers_VPRT
its_PIT
UK_NN
wholesale_JJ
customers_NN
access_NN
to_PIN
long-term_JJ
financing_GER
for_PIN
their_TPP3
pharmacy_NN
businesses_NOMZ
through_PIN
financing_VBG
arrangements_NOMZ
developed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
with_PIN
its_PIT
banks_NN
._.
The_DT
Company_NN
supports_VPRT
these_DEMO
arrangements_NOMZ
through_PIN
the_DT
provision_NN
of_PIN
guarantees_NN
,_,
which_WDT [SERE]
at_PIN
31_CD
December_NN
2005_CD
amounted_VBD
to_PIN
19.6_CD
million_CD
2004_CD
18.6_CD
million_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
written_VBN [PUBV]
a_DT
number_NN
of_PIN
guarantees_NN
in_PIN
relation_NOMZ
to_PIN
third_JJ
party_NN
funding_GER
arrangements_NOMZ
with_PIN
subsidiaries_NN
._.
These_DEMO
guarantees_NN
can_POMD [SPAU]
only_DWNT
be_VB [BYPA]
exercised_VBN
by_PIN
the_DT
lender_NN
in_PIN
the_DT
event_NN
of_PIN
predefined_JJ
events_NN
all_QUAN
of_PIN
which_WDT [PIRE]
reflect_VPRT [PRIV]
financial_JJ
risks_NN
._.
Therefore_CONJ
these_DEMO
agreements_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
IAS_NN
37_CD
._.
Guarantees_NN
are_VPRT [SPAU] [BYPA]
also_RB
provided_VBN
by_PIN
another_DT
Group_NN
company_NN
that_TSUB
totalled_VBD
11.3_CD
million_CD
at_PIN
31_CD
December_NN
2005_CD
2004_CD
30.7_CD
million_CD
._.
Total_JJ
loans_NN
outstanding_JJ
through_PIN
these_DEMP
financing_VBG
arrangements_NOMZ
at_PIN
31_CD
December_NN
2005_CD
were_VBD [BEMA]
205.6_CD
million_CD
2004_CD
205.8_CD
million_CD
._.
On_PIN
31_CD
December_NN
2005_CD
the_DT
total_JJ
extent_NN
of_PIN
these_DEMO
guarantees_NN
amounted_VBD
to_PIN
30.9_CD
million_CD
2004_CD
49.3_CD
million_CD
._.
In_PIN
the_DT
last_JJ
five_CD
years_NN
the_DT
Group_NN
has_VPRT [PEAS]
not_XX0
suffered_VBN
any_QUAN
loss_NN
in_PIN
relation_NOMZ
to_PIN
these_DEMO
schemes_NN
._.
49_CD
POST_NN
BALANCE_NN
SHEET_NN
EVENTS_NN
On_PIN
17_CD
February_NN
2006_CD
the_DT
Group_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
reached_VBN
an_DT
agreement_NOMZ
to_TO
enter_VB
the_DT
Russian_JJ
pharmaceutical_JJ
wholesale_JJ
market_NN
through_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
96_CD
%_NN
controlling_VBG [WZPRES]
stake_NN
in_PIN
A._NN
P._NN
Apteka_NN
Holding_GER
Limited_NN
,_,
the_DT
parent_NN
company_NN
of_PIN
Apteka_NN
Holding_GER
ZAO_NN
,_,
for_PIN
a_DT
consideration_NOMZ
of_PIN
approximately_RB
18_CD
million_CD
._.
In_CONJ
addition_NULL
the_DT
Group_NN
will_PRMD
assume_VB [PRIV]
approximately_RB
10_CD
million_CD
of_PIN
net_JJ
debt_NN
._.
The_DT
Group_NN
will_PRMD
have_VB
an_DT
option_NOMZ
to_TO
acquire_VB
the_DT
remaining_VBG
4_CD
%_NN
of_PIN
A._NN
P._NN
Apteka_NN
Holding_GER
Limited_NN
within_PIN
three_CD
to_PIN
six_CD
years_NN
._.
The_DT
transaction_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
conditional_PRED
upon_PIN
receiving_VBG
regulatory_JJ
approval_NN
,_,
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [BYPA]
completed_VBN
by_PIN
the_DT
end_NN
of_PIN
March_NN
2006_CD
._.
50_CD
TRANSITION_NOMZ
TO_PIN
IFRS_NN
All_QUAN
references_NN
to_PIN
UK_NN
GAAP_NN
in_PIN
this_DEMO
note_NN
are_VPRT [BEMA]
to_PIN
UK_NN
GAAP_NN
applicable_JJ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
._.
This_DEMP
is_VPRT [BEMA]
the_DT
first_JJ
year_NN
that_TOBJ
the_DT
Group_NN
has_VPRT [PEAS]
presented_VBN
its_PIT
financial_JJ
statements_NOMZ
under_IN
IFRS_NN
._.
The_DT
last_JJ
financial_JJ
statements_NOMZ
under_IN
UK_NN
GAAP_NN
were_VBD [BEMA]
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
and_CC
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
was_VBD [BEMA]
1_CD
January_NN
2004_CD
._.
On_PIN
18_CD
July_NN
2005_CD
,_,
the_DT
Group_NN
published_VBD
detailed_JJ
income_NN
statement_NOMZ
and_PHC
balance_NN
sheet_NN
reconciliations_NOMZ
of_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
an_DT
abridged_JJ
extract_VB
of_PIN
the_DT
published_VBN
document_NOMZ
describing_VBG [WZPRES]
the_DT
effects_NN
of_PIN
adoption_NOMZ
of_PIN
IFRS_NN
and_CC
the_DT
reconciliations_NOMZ
required_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
of_PIN
transition_NOMZ
._.
Summary_NN
of_PIN
the_DT
effects_NN
of_PIN
IFRS_NN
adoption_NOMZ
The_DT
principal_JJ
impacts_NN
of_PIN
IFRS_NN
on_PIN
the_DT
Groups_NN
2004_CD
financial_JJ
statements_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
recognition_NOMZ
of_PIN
a_DT
charge_NN
for_PIN
the_DT
fair_JJ
value_NN
of_PIN
share-based_JJ
compensation_NOMZ
:_:
requirement_NOMZ
not_XX0
to_TO
amortise_VB
goodwill_NN
:_:
recognition_NOMZ
of_PIN
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
on_PIN
pharmacy_NN
licences_NN
,_,
unremitted_JJ
earnings_GER
of_PIN
associates_NN
and_CC
rolled_VBD
over_IN
capital_NN
gains_NN
:_:
and_ANDC
recognition_NOMZ
of_PIN
dividends_NN
only_DWNT
when_RB
they_TPP3
are_VPRT [PASS]
declared_VBN [PUBV]
rather_RB
than_PIN
when_RB
proposed_VBN [SUAV]
._.
In_PIN
terms_NN
of_PIN
the_DT
2004_CD
results_NN
,_,
reported_VBD [PUBV] [THATD]
profits_NN
increased_VBN
under_IN
IFRS_NN
,_,
mainly_RB
because_CAUS
of_PIN
the_DT
reversal_NN
of_PIN
goodwill_NN
amortisation_NOMZ
and_CC
the_DT
reversal_NN
of_PIN
goodwill_NN
recycled_VBN [WZPAST]
from_PIN
reserves_NN
on_PIN
the_DT
disposal_NN
of_PIN
subsidiaries_NN
._.
Impact_NN
on_PIN
profit_NN
Excluding_VBG [WZPRES]
goodwill_NN
amortisation_NOMZ
,_,
the_DT
profit_NN
on_PIN
disposal_NN
of_PIN
subsidiaries_NN
and_PHC
amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
investments_NOMZ
,_,
the_DT
effect_NN
of_PIN
adoption_NOMZ
of_PIN
IFRS_NN
was_VBD [BEMA]
not_XX0
significant_PRED
._.
The_DT
Group_NN
considers_VPRT [PRIV]
the_DT
measurement_NOMZ
of_PIN
profit_NN
excluding_VBG [WZPRES]
these_DEMO
items_NN
to_TO
be_VB [BEMA]
a_DT
useful_JJ
indication_NOMZ
of_PIN
underlying_VBG
performance_NN
._.
The_DT
reduction_NOMZ
in_PIN
profits_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
requirement_NOMZ
to_TO
recognize_VB [PRIV]
a_DT
charge_NN
for_PIN
the_DT
fair_JJ
value_NN
of_PIN
share-based_JJ
compensation_NOMZ
awards_NN
was_VBD [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
the_DT
net_JJ
credit_NN
arising_VBG [WZPRES]
from_PIN
the_DT
movements_NOMZ
in_PIN
deferred_JJ
taxation_NOMZ
liabilities_NOMZ
recognized_VBN [PRIV] [WZPAST]
on_PIN
unremitted_JJ
earnings_GER
of_PIN
associates_NN
,_,
pharmacy_NN
licences_NN
and_CC
rolled_VBD
over_IN
capital_NN
gains_NN
._.
Impact_NN
on_PIN
net_JJ
assets_NN
Net_JJ
assets_NN
at_PIN
31_CD
December_NN
2004_CD
decreased_VBN
under_IN
IFRS_NN
._.
This_DEMP
was_VBD [BEMA]
predominantly_RB
due_PRED
to_PIN
the_DT
recognition_NOMZ
of_PIN
additional_JJ
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
under_IN
IFRS_NN
as_IN
a_DT
general_JJ
principle_NN
,_,
the_DT
recognition_NOMZ
of_PIN
deferred_VBN
taxation_NOMZ
liabilities_NOMZ
is_VPRT [BEMA]
more_EMPH
comprehensive_PRED
under_IN
IFRS_NN
than_PIN
UK_NN
GAAP_NN
._.
Partially_DWNT
offsetting_VBG
this_DEMO
reduction_NOMZ
in_PIN
net_JJ
assets_NN
was_VBD [BEMA]
the_DT
reversal_NN
of_PIN
the_DT
2004_CD
goodwill_NN
amortisation_NOMZ
charge_NN
and_CC
the_DT
accrual_NN
for_PIN
the_DT
proposed_VBN [SUAV]
2004_CD
final_JJ
dividend_NN
._.
